

CORRECTION OPEN



Correction: Inequalities in treatment among patients with colon and rectal cancer: a multistate survival model using data from England National Cancer Registry 2012–2016

Suping Ling , Miguel-Angel Luque Fernandez , Manuela Quaresma, Aurelien Belot and Bernard Rchet

© The Author(s) 2023

British Journal of Cancer (2023) 129:2035–2038; <https://doi.org/10.1038/s41416-023-02486-6>

Correction to: *British Journal of Cancer* <https://doi.org/10.1038/s41416-023-02440-6>, published online 23 September 2023

In this article table 1 has been given erroneously:

Table 1. Baseline characteristics of included patients with colon ($N = 70,705$) or rectal ($N = 41,991$) cancer in England between 2012 and 2016.

Colon cancer	Total $N = 70,705$	Stage I $N = 11,832$	Stage II $N = 19,083$	Stage III $N = 21,354$	Stage IV $N = 18,436$
Age at diagnosis, years	73.1 (64.4–80.6)	71.2 (62.9–78.7)	74.2 (66.1–81.3)	72.7 (64.2–80.4)	73.2 (63.8–81.4)
Age group, years					
18–44	2727 (3.9%)	734 (6.2%)	625 (3.3%)	707 (3.3%)	661 (3.6%)
45–54	4333 (6.1%)	615 (5.2%)	977 (5.1%)	1398 (6.5%)	1343 (7.3%)
55–64	11,741 (16.6%)	2198 (18.6%)	2709 (14.2%)	3744 (17.5%)	3090 (16.8%)
65–74	21,435 (30.3%)	4076 (34.4%)	5739 (30.1%)	6512 (30.5%)	5108 (27.7%)
74–84	21,875 (30.9%)	3198 (27.0%)	6522 (34.2%)	6549 (30.7%)	5606 (30.4%)
≥85	8594 (12.2%)	1011 (8.5%)	2511 (13.2%)	2444 (11.4%)	2628 (14.3%)
Sex					
Men	37,954 (53.7%)	6662 (56.3%)	10,148 (53.2%)	11,242 (52.6%)	9902 (53.7%)
Women	32,751 (46.3%)	5170 (43.7%)	8935 (46.8%)	10,112 (47.4%)	8534 (46.3%)
Ethnicity					
White	67,221 (95.1%)	11,258 (95.1%)	18,258 (95.7%)	20,219 (94.7%)	17,486 (94.8%)
Other ethnicities	3484 (4.9%)	574 (4.9%)	825 (4.3%)	1135 (5.3%)	950 (5.2%)
Income 2015 quintile					
1 – Least deprived	15,612 (22.1%)	2655 (22.4%)	4211 (22.1%)	4840 (22.7%)	3906 (21.2%)
2	16,374 (23.2%)	2769 (23.4%)	4505 (23.6%)	5005 (23.4%)	4095 (22.2%)
3	14,919 (21.1%)	2454 (20.7%)	4098 (21.5%)	4435 (20.8%)	3932 (21.3%)
4	12,946 (18.3%)	2144 (18.1%)	3498 (18.3%)	3861 (18.1%)	3443 (18.7%)
5 – Most deprived	10,854 (15.4%)	1810 (15.3%)	2771 (14.5%)	3213 (15.0%)	3060 (16.6%)
Comorbidity					
Heart failure	2248 (3.2%)	367 (3.1%)	635 (3.3%)	608 (2.8%)	638 (3.5%)
Myocardial infarction	2966 (4.2%)	488 (4.1%)	891 (4.7%)	857 (4.0%)	730 (4.0%)
Diabetes with complications	529 (0.7%)	94 (0.8%)	141 (0.7%)	139 (0.7%)	155 (0.8%)

Colon cancer					
	Total N = 70,705	Stage I N = 11,832	Stage II N = 19,083	Stage III N = 21,354	Stage IV N = 18,436
Chronic pulmonary disease	8935 (12.6%)	1635 (13.8%)	2488 (13.0%)	2490 (11.7%)	2322 (12.6%)
Route to diagnosis					
Emergency presentation	12,980 (18.4%)	1227 (10.4%)	3225 (16.9%)	3337 (15.6%)	5191 (28.2%)
GP referral	17,798 (25.2%)	3393 (28.7%)	4618 (24.2%)	5370 (25.1%)	4417 (24.0%)
Inpatient elective	2521 (3.6%)	492 (4.2%)	667 (3.5%)	802 (3.8%)	560 (3.0%)
Other outpatient	5221 (7.4%)	959 (8.1%)	1512 (7.9%)	1409 (6.6%)	1,341 (7.3%)
Screening	8754 (12.4%)	2870 (24.3%)	2357 (12.4%)	2762 (12.9%)	765 (4.1%)
TWW	23,431 (33.1%)	2891 (24.4%)	6704 (35.1%)	7674 (35.9%)	6162 (33.4%)
Rectal cancer	Total	Stage I	Stage II	Stage III	Stage IV
	N = 41,991	N = 9510	N = 7504	N = 16,346	N = 8631
Age at diagnosis, years	70.2 (61.5–78.2)	70.6 (63.0–78.2)	72.6 (63.7–80.1)	68.7 (60.2–77.0)	70.4 (60.6–78.8)
Age group, years					
18–44	1401 (3.3%)	232 (2.4%)	184 (2.5%)	646 (4.0%)	339 (3.9%)
45–54	3723 (8.9%)	675 (7.1%)	521 (6.9%)	1677 (10.3%)	850 (9.8%)
55–64	9076 (21.6%)	1969 (20.7%)	1392 (18.6%)	3890 (23.8%)	1825 (21.1%)
65–74	13,217 (31.5%)	3398 (35.7%)	2237 (29.8%)	5113 (31.3%)	2469 (28.6%)
74–84	11,067 (26.4%)	2460 (25.9%)	2341 (31.2%)	3982 (24.4%)	2284 (26.5%)
≥85	3507 (8.4%)	776 (8.2%)	829 (11.0%)	1038 (6.4%)	864 (10.0%)
Sex					
Male	26,804 (63.8%)	5844 (61.5%)	4815 (64.2%)	10,579 (64.7%)	5566 (64.5%)
Female	15,187 (36.2%)	3666 (38.5%)	2689 (35.8%)	5767 (35.3%)	3065 (35.5%)
Ethnicity					
White	39,935 (95.1%)	9075 (95.4%)	7143 (95.2%)	15,522 (95.0%)	8195 (94.9%)
Other ethnicities	2056 (4.9%)	435 (4.6%)	361 (4.8%)	824 (5.0%)	436 (5.1%)
Income 2015 quintile					
1 – Least deprived	8815 (21.0%)	2138 (22.5%)	1614 (21.5%)	3389 (20.7%)	1674 (19.4%)
2	9488 (22.6%)	2248 (23.6%)	1705 (22.7%)	3705 (22.7%)	1830 (21.2%)
3	8965 (21.3%)	2046 (21.5%)	1564 (20.8%)	3520 (21.5%)	1835 (21.3%)
4	7865 (18.7%)	1685 (17.7%)	1425 (19.0%)	3012 (18.4%)	1743 (20.2%)
5 – Most deprived	6858 (16.3%)	1393 (14.6%)	1196 (15.9%)	2720 (16.6%)	1549 (17.9%)
Comorbidity					
Heart failure	859 (2.0%)	239 (2.5%)	176 (2.3%)	245 (1.5%)	199 (2.3%)
Myocardial infarction	1349 (3.2%)	375 (3.9%)	269 (3.6%)	435 (2.7%)	270 (3.1%)
Diabetes with complications	259 (0.6%)	67 (0.7%)	50 (0.7%)	91 (0.6%)	51 (0.6%)
Chronic pulmonary disease	4292 (10.2%)	1141 (12.0%)	820 (10.9%)	1415 (8.7%)	916 (10.6%)
Route to diagnosis					
Emergency presentation	2920 (7.0%)	356 (3.7%)	522 (7.0%)	791 (4.8%)	1251 (14.5%)
GP referral	11,226 (26.7%)	2969 (31.2%)	1935 (25.8%)	4193 (25.7%)	2129 (24.7%)
Inpatient elective	1557 (3.7%)	400 (4.2%)	261 (3.5%)	599 (3.7%)	297 (3.4%)
Other outpatient	2281 (5.4%)	730 (7.7%)	435 (5.8%)	687 (4.2%)	429 (5.0%)
Screening	5215 (12.4%)	1997 (21.0%)	858 (11.4%)	1927 (11.8%)	433 (5.0%)
TWW	18,792 (44.8%)	3058 (32.2%)	3493 (46.5%)	8149 (49.9%)	4092 (47.4%)

TWW: 2-week-wait referral; comorbidity: patients can have more than one condition listed.

It should be read:

Table 1. Baseline characteristics of included patients with colon ($N = 70,705$) or rectal ($N = 41,991$) cancer in England between 2012 and 2016.

<i>Colon cancer</i>	Total $N = 70,705$	Stage I $N = 11,832$	Stage II $N = 19,083$	Stage III $N = 21,354$	Stage IV $N = 18,436$
Age at diagnosis, years	73.1 (64.4–80.6)	71.2 (62.9–78.7)	74.2 (66.1–81.3)	72.7 (64.2–80.4)	73.2 (63.8–81.4)
Age group, years					
18–44	2727 (3.9%)	734 (6.2%)	625 (3.3%)	707 (3.3%)	661 (3.6%)
45–54	4333 (6.1%)	615 (5.2%)	977 (5.1%)	1398 (6.5%)	1343 (7.3%)
55–64	11,741 (16.6%)	2198 (18.6%)	2709 (14.2%)	3744 (17.5%)	3090 (16.8%)
65–74	21,435 (30.3%)	4076 (34.4%)	5739 (30.1%)	6512 (30.5%)	5108 (27.7%)
74–84	21,875 (30.9%)	3198 (27.0%)	6522 (34.2%)	6549 (30.7%)	5606 (30.4%)
≥85	8594 (12.2%)	1011 (8.5%)	2511 (13.2%)	2444 (11.4%)	2628 (14.3%)
Sex					
Men	37,954 (53.7%)	6662 (56.3%)	10,148 (53.2%)	11,242 (52.6%)	9902 (53.7%)
Women	32,751 (46.3%)	5170 (43.7%)	8935 (46.8%)	10,112 (47.4%)	8534 (46.3%)
Ethnicity					
White	67,221 (95.1%)	11,258 (95.1%)	18,258 (95.7%)	20,219 (94.7%)	17,486 (94.8%)
Other ethnicities	3484 (4.9%)	574 (4.9%)	825 (4.3%)	1135 (5.3%)	950 (5.2%)
Income 2015 quintile					
1 – Least deprived	15,612 (22.1%)	2655 (22.4%)	4211 (22.1%)	4840 (22.7%)	3906 (21.2%)
2	16,374 (23.2%)	2769 (23.4%)	4505 (23.6%)	5005 (23.4%)	4095 (22.2%)
3	14,919 (21.1%)	2454 (20.7%)	4098 (21.5%)	4435 (20.8%)	3932 (21.3%)
4	12,946 (18.3%)	2144 (18.1%)	3498 (18.3%)	3861 (18.1%)	3443 (18.7%)
5 – Most deprived	10,854 (15.4%)	1810 (15.3%)	2771 (14.5%)	3213 (15.0%)	3060 (16.6%)
Comorbidity					
Heart failure	2248 (3.2%)	367 (3.1%)	635 (3.3%)	608 (2.8%)	638 (3.5%)
Myocardial infarction	2966 (4.2%)	488 (4.1%)	891 (4.7%)	857 (4.0%)	730 (4.0%)
Diabetes with complications	529 (0.7%)	94 (0.8%)	141 (0.7%)	139 (0.7%)	155 (0.8%)
Chronic pulmonary disease	8935 (12.6%)	1635 (13.8%)	2488 (13.0%)	2490 (11.7%)	2322 (12.6%)
Route to diagnosis					
Emergency presentation	12,980 (18.4%)	1227 (10.4%)	3225 (16.9%)	3337 (15.6%)	5191 (28.2%)
GP referral	17,798 (25.2%)	3393 (28.7%)	4618 (24.2%)	5370 (25.1%)	4417 (24.0%)
Inpatient elective	2521 (3.6%)	492 (4.2%)	667 (3.5%)	802 (3.8%)	560 (3.0%)
Other outpatient	5221 (7.4%)	959 (8.1%)	1512 (7.9%)	1409 (6.6%)	1,341 (7.3%)
Screening	8754 (12.4%)	2870 (24.3%)	2357 (12.4%)	2762 (12.9%)	765 (4.1%)
TWW	23,431 (33.1%)	2891 (24.4%)	6704 (35.1%)	7674 (35.9%)	6162 (33.4%)
<i>Rectal cancer</i>	Total $N = 41,991$	Stage I $N = 9510$	Stage II $N = 7504$	Stage III $N = 16,346$	Stage IV $N = 8631$
Age at diagnosis, years	70.2 (61.5–78.2)	70.6 (63.0–78.2)	72.6 (63.7–80.1)	68.7 (60.2–77.0)	70.4 (60.6–78.8)
Age group, years					
18–44	1401 (3.3%)	232 (2.4%)	184 (2.5%)	646 (4.0%)	339 (3.9%)
45–54	3723 (8.9%)	675 (7.1%)	521 (6.9%)	1677 (10.3%)	850 (9.8%)
55–64	9076 (21.6%)	1969 (20.7%)	1392 (18.6%)	3890 (23.8%)	1825 (21.1%)
65–74	13,217 (31.5%)	3398 (35.7%)	2237 (29.8%)	5113 (31.3%)	2469 (28.6%)
74–84	11,067 (26.4%)	2460 (25.9%)	2341 (31.2%)	3982 (24.4%)	2284 (26.5%)
≥85	3507 (8.4%)	776 (8.2%)	829 (11.0%)	1038 (6.4%)	864 (10.0%)
Sex					
Male	26,804 (63.8%)	5844 (61.5%)	4815 (64.2%)	10,579 (64.7%)	5566 (64.5%)
Female	15,187 (36.2%)	3666 (38.5%)	2689 (35.8%)	5767 (35.3%)	3065 (35.5%)
Ethnicity					
White	39,935 (95.1%)	9075 (95.4%)	7143 (95.2%)	15,522 (95.0%)	8195 (94.9%)
Other ethnicities	2056 (4.9%)	435 (4.6%)	361 (4.8%)	824 (5.0%)	436 (5.1%)

<i>Rectal cancer</i>	Total N = 41,991	Stage I N = 9510	Stage II N = 7504	Stage III N = 16,346	Stage IV N = 8631
Income 2015 quintile					
1 – Least deprived	8815 (21.0%)	2138 (22.5%)	1614 (21.5%)	3389 (20.7%)	1674 (19.4%)
2	9488 (22.6%)	2248 (23.6%)	1705 (22.7%)	3705 (22.7%)	1830 (21.2%)
3	8965 (21.3%)	2046 (21.5%)	1564 (20.8%)	3520 (21.5%)	1835 (21.3%)
4	7865 (18.7%)	1685 (17.7%)	1425 (19.0%)	3012 (18.4%)	1743 (20.2%)
5 – Most deprived	6858 (16.3%)	1393 (14.6%)	1196 (15.9%)	2720 (16.6%)	1549 (17.9%)
Comorbidity					
Heart failure	859 (2.0%)	239 (2.5%)	176 (2.3%)	245 (1.5%)	199 (2.3%)
Myocardial infarction	1349 (3.2%)	375 (3.9%)	269 (3.6%)	435 (2.7%)	270 (3.1%)
Diabetes with complications	259 (0.6%)	67 (0.7%)	50 (0.7%)	91 (0.6%)	51 (0.6%)
Chronic pulmonary disease	4292 (10.2%)	1141 (12.0%)	820 (10.9%)	1415 (8.7%)	916 (10.6%)
Route to diagnosis					
Emergency presentation	2920 (7.0%)	356 (3.7%)	522 (7.0%)	791 (4.8%)	1251 (14.5%)
GP referral	11,226 (26.7%)	2969 (31.2%)	1935 (25.8%)	4193 (25.7%)	2129 (24.7%)
Inpatient elective	1557 (3.7%)	400 (4.2%)	261 (3.5%)	599 (3.7%)	297 (3.4%)
Other outpatient	2281 (5.4%)	730 (7.7%)	435 (5.8%)	687 (4.2%)	429 (5.0%)
Screening	5215 (12.4%)	1997 (21.0%)	858 (11.4%)	1927 (11.8%)	433 (5.0%)
TWW	18,792 (44.8%)	3058 (32.2%)	3493 (46.5%)	8149 (49.9%)	4092 (47.4%)

TWW: 2-week-wait referral; comorbidity: patients can have more than one condition listed.

The original article has been corrected.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party

material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023